U.S. Markets closed

J&J Predicts A Revenue Slowdown — Prodding Biotech, Pharma Stocks To Dip

ALLISON GATLIN
J&J Predicts A Revenue Slowdown — Prodding Biotech, Pharma Stocks To Dip

Johnson & Johnson stock stumbled Tuesday after the Dow Jones component's 2019 guide lagged forecasts despite a better-than-expected fourth quarter. Sales from four key blockbusters grew.